CAL02

Indicaton

CAL02 is a first-in-class broad-spectrum anti-virulence agent for the treatment and prevention of complications associated with severe or resistant infections. First-in-man clinical trial in patients completed.

Therapeutic indications

Type of product

Other

Table

Phase

Phase I completed
Available in

WW

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

AUP-16 (AUP1602-C)

AUP-16 is a multi-therapy live bacterial vector for chronic wounds: Diabetic Foot, Leg & Pressure Ulcers

Phase II started

Regkirona (regdanvimab)

Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19

Marketed